Molecular docking studies of squalen synthase inhibitors as potential anti cardiovascular disease drugs: Insights into drug-protein interaction discovery

Pharmaceutical Sciences

Volumn 19, Issue 2, 2013, Pages 39-44

  Raeisi, Salimeh ^a  

^a SHAHREKORD UNIVERSITY   (Iran)

Author keywords

Binding free energy; Hypercholesterolemia; Molecular docking; Squalen synthase inhibitor

Indexed keywords

CARDIOVASCULAR AGENT; SQUALENE SYNTHASE INHIBITOR;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG BINDING; DRUG BINDING SITE; DRUG DESIGN; ENERGY; HYDROPHOBICITY; MOLECULAR DOCKING;

EID: 84904003141     PISSN: 1735403X     EISSN: 23832886     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Griebenow N, Buchmueller A, Kolkhof P, Schamberger J, Bischoff H. Identification of 4H,6H-[2]benzoxepino[4,5-c][1,2]oxazoles as novel squalene synthase inhibitors. Bioorg Med Chem Lett 2011;21(12):3648-53.
2. Ishihara T, Kakuta H, Moritani H, Ugawa T, Sakamoto S, Tsukamoto S, et al. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorg Med Chem 2003;11(17):3735-45. (Pubitemid 36952271)
3. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108(3):391-7. (Pubitemid 32730785)
4. Hunninghake DB. HMG CoA reductase inhibitors. Curr Opin Lipidol 1992;3(1):22-8.
5. Prospective Studies C, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370(9602):1829-39.
6. Nishimoto T, Tozawa R, Amano Y, Wada T, Imura Y, Sugiyama Y. Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003;66(11):2133-9. (Pubitemid 37377859)
7. Kourounakis AP, Matralis AN, Nikitakis A. Design of more potent squalene synthase inhibitors with multiple activities. Bioorg Med Chem 2010;18(21):7402-12.
8. Golomb BA, Evans MA. Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8(6):373-418.
9. Soltis DA, Mcmahon G, Caplan SL, Dudas DA, Chamberlin HA, Vattay A, et al. Expression, purification, and characterization of the human squalene synthase: use of yeast and baculoviral systems. Arch Biochem Biophys 1995;316(2):713-23.
10. Thompson JF, Danley DE, Mazzalupo S, Milos PM, Lira ME, Harwood HJ. Truncation of human squalene synthase yields active, crystallizable protein. Arch Biochem Biophys 1998;350(2):283-90. (Pubitemid 28368655)
11. Alberts AW, Berger GD, Bergstrom JD. Squalene synthetase inhibitors. Google Patents; 1992.
12. Cavasotto CN, Orry AJ. Ligand docking and structure-based virtual screening in drug discovery. Curr Top Med Chem 2007;7(10):1006-14. (Pubitemid 47040528)
13. Morris GM, Lim-Wilby M. Molecular docking. Methods Mol Boil 2008;443:365-82.
14. Sealey-Cardona M, Cammerer S, Jones S, Ruiz-Perez LM, Brun R, Gilbert IH, et al. Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother 2007;51(6):2123-9. (Pubitemid 46903104)
15. Choi SW, Hur NY, Ahn SC, Kim DS, Lee JK, Kim DO, et al. Isolation and structural determination of squalene synthase inhibitor from Prunus mume fruit. J Microbiol Biotechnol 2007;17(12):1970-5.
16. Lee S, Poulter CD. Cloning, solubilization, and characterization of squalene synthase from Thermosynechococcus elongatus BP-1. J Bacteriol 2008;190(11):3808-16. (Pubitemid 351732859)
17. Laxmi D, Priyadarshy S. HyperChem 7. Biotech Software and Internet Report: The Computer Software Journal for Scientists. 2002;3(1):5-9.
18. Lindstrom W, Morris GM, Weber C, Huey R. Using AutoDock for virtual screening. La Jolla, CA: The Scripps Research Institute Molecular Graphics Laboratory; 2006.
19. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDock Tools4: Automated docking with selective receptor flexibility. J Comput Chem 2009;30(16):2785-91.
20. Morris GM, Huey R, Olson AJ. Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics 2008;Chapter 8:Unit 8 14.
21. Huey R, Morris GM. Using AutoDock with AutoDock Tools: A Tutorial. La Jolla, CA: The Scripps Research Institute, Molecular Graphics Laboratory; 2003.
22. Goodsell DS. Computational docking of biomolecular complexes with AutoDock. Cold Spring Harb Protoc 2009;2009(5):pdb prot5200.
23. Saladin A, Fiorucci S, Poulain P, Prevost C, Zacharias M. PTools: an opensource molecular docking library. BMC struct boil 2009;9:27.
24. Choi SW, Hur NY, Ahn SC, Kim DS, Lee JK, Kim DO, et al. Isolation and structural determination of squalene synthase inhibitor from Prunus mume fruit. J Microbiol Biotechnol 2007;17(12):1970-5.
25. Scheer M, Grote A, Chang A, Schomburg I, Munaretto C, Rother M, et al. BRENDA, The Comprehensive Enzyme Information System in 2011. Nucleic Acids Res 2011;39:D670-7.
26. Pandit J, Danley DE, Schulte GK, Mazzalupo S, Pauly TA, Hayward CM, et al. Crystal structure of human squalene synthase. A key enzyme in cholesterol biosynthesis. J Biol Chem 2000;275(39):30610-7.
27. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 1995;8(2):127-34.
28. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14(1):33-8, 27-8. (Pubitemid 26152973)
29. William H, Andrew D, Klaus S. VMD: visual molecular dynamics. J Mol Grap 1996;14:33-8.